Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Revenue of Aurinia Pharmaceuticals Inc. (AUPH)
Revenue in 2023 (TTM): $175.51 M
According to Aurinia Pharmaceuticals Inc.'s latest financial reports the company's current revenue (TTM) is $175.51 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aurinia Pharmaceuticals Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $175.51 M | $161.37 M | $-71,665,000 | $-77,469,000 | $-78,020,000 |
| 2022 | $134.03 M | $128.37 M | $-111,470,000 | $-106,352,000 | $-108,180,000 |
| 2021 | $45.61 M | $44.51 M | $-178,637,000 | $-180,206,000 | $-180,966,000 |
| 2020 | $50.12 M | $-209,000 | $-96,192,000 | $-102,774,000 | $-102,680,000 |
| 2019 | $318 K | $-52,548,000 | $-80,991,000 | $-123,702,000 | $-123,846,000 |
| 2018 | $463 K | $-40,919,000 | $-44,639,000 | $-64,047,000 | $-64,120,000 |
| 2017 | $420 K | $419 K | $-21,683,000 | $-70,792,000 | $-70,792,000 |
| 2016 | $173 K | $169 K | $-20,827,000 | $-23,295,000 | $-23,295,000 |
| 2015 | $235 K | $223 K | $-26,945,000 | $-18,607,000 | $-18,607,000 |
| 2014 | $278 K | $241 K | $-15,696,000 | $-16,647,000 | $-16,647,000 |
| 2013 | $948.56 K | $947.62 K | $-3,214,779 | $-6,402,322 | $-2,546,090 |
| 2012 | $6.16 M | $6.11 M | $-4,655,067 | $-9,738,347 | $-9,737,342 |
| 2011 | $927.52 K | $742.41 K | $-1,445,642 | $-2,407,444 | $-2,407,444 |
| 2010 | $3.42 M | $3.37 M | $-4,312,310 | $-5,459,127 | $-3,660,414 |
| 2009 | $4.05 M | $3.48 M | $-7,742,336 | $-7,598,128 | $-7,598,128 |
| 2008 | $3.88 M | $1.76 M | $-14,216,927 | $-15,881,676 | $-15,881,676 |
| 2007 | $2.33 M | $1.28 M | $-34,261,335 | $-33,822,074 | $-33,822,074 |
| 2006 | $3.52 M | $2.93 M | $-22,602,093 | $-22,853,466 | $-22,852,608 |
| 2005 | $1.18 M | $1.18 M | $-28,153,091 | $-29,074,393 | $-29,075,254 |
| 2004 | $1.27 M | $1.27 M | $-20,832,016 | $-22,556,441 | $-22,559,768 |
| 2003 | $7.66 M | $7.66 M | $-9,829,037 | $-14,519,923 | $-14,646,391 |
| 2002 | $11.92 M | $11.23 M | $-861,965 | $-294,097 | $-365,875 |
| 2001 | $5.3 M | $4.27 M | $-7,198,583 | $-7,349,339 | $-7,404,616 |
| 2000 | $902.77 K | $222.11 K | $-6,329,180 | $-6,271,210 | $-6,284,888 |
| 1999 | $1.36 M | $679.1 K | $-1,018,648 | $ | $-1,222,378 |
| 1998 | $781.25 K | $260.42 K | $-2,408,854 | $-2,343,750 | $-2,213,542 |